NASDAQ$RCMT

RCM Technologies Inc · Q2 2025 earnings

Q2 2025 earnings · · After market close · Investor relations

Briefing

RCM Technologies posted Q2 2025 revenue of $78.2M and net income of $3.8M, driven by growth across all segments.

RCM Technologies delivered strong Q2 2025 results with revenue up 13% year-over-year to $78.2M, supported by increases in Specialty Health Care, Engineering, and Life Sciences, Data & Solutions. Net income remained steady at $3.8M, while adjusted EBITDA grew to $8.1M. Gross profit margin stayed healthy at 28.5%.

  • Revenue grew 13% YoY to $78.2M, with contributions from all segments.
  • Net income was $3.8M, matching prior-year quarter performance.
  • Adjusted EBITDA rose to $8.1M from $7.2M last year.
  • Gross profit margin held steady at 28.5%.

Headline financials

Total Revenue

$78.2M

Previous: $69.2M+13.0%
EPS (adj)

$0.69

Previous: $0.47+46.8%
Adjusted EBITDA

$8.14M

Previous: $7.21M+12.9%
Cash Flow from Operations

-$7.88M

Previous: $5.73M-237.6%
Net Debt

$28.5M

No prior period
Gross Profit Margin

28.5%

Previous: 28.9%-1.4%
Capital Expenditures

-$900K

Previous: -$1.07M+15.7%
Net Income

$3.79M

Previous: $3.76M+0.6%
Operating Income

$6.6M

Previous: $5.82M+13.4%
Gross Profit

$22.3M

Previous: $20M+11.4%

Revenue & EPS history

RCM Technologies · Revenue · Quarterly

$78.2M

Q2 2025+13%vs Q2 2024
Beat estimate in 3 of 15 quarters(20%)
ActualEstimate

Revenue by segment

RCM Technologies · $83M total across 3 segments · Q1 2026

  • Specialty Healthcare
    $48.1M
  • Engineering
    $26.1M
  • Life Sciences, Data and Solutions
    $8.8M

Forward guidance

RCM Technologies anticipates a strong second half of 2025, with continued momentum in Engineering and resilience across all segments.

Tailwinds

  • Sustained growth across all three segments.
  • Engineering segment showing increasing momentum.
  • Healthy gross profit margins across business lines.
  • Adjusted EPS up 21% year-over-year.
  • Diversified service offerings supporting growth.

Headwinds

  • Life Sciences, Data & Solutions revenue declined YoY.
  • Negative operating cash flow in the quarter.
  • Net debt remains elevated at $28.5M.
  • Continued reliance on line of credit borrowings.
  • Competitive market conditions could pressure margins.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

-0.2%

Avg return

Earnings day

+2.6%

Avg return

5 days after

+8.2%

Avg return

30 days after

46%

30 / 65 earnings

Positive

+48.2%

Q1 2022

Best reaction

-25.0%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.6%-23.2%
Q4 2025+4.3%+44.6%+61.5%
Q3 2025-9.3%-13.0%-9.6%
Q2 2025-4.6%+1.1%+14.9%
Q1 2025+0.8%-1.0%-2.1%
Q4 2024-13.5%-10.2%-10.9%
Q3 2024+5.2%+13.5%+5.1%
Q2 2024+6.1%+2.1%+4.6%
Q1 2024+8.8%+12.8%+2.7%
Q4 2023-25.0%-23.5%-32.4%
Q3 2023+14.7%+31.0%+41.7%
Q2 2023-12.3%+3.2%-1.5%
Q1 2023+5.1%+15.2%+39.2%
Q4 2022+0.3%-4.5%-6.3%
Q3 2022-12.3%-19.4%-28.2%
Q2 2022-16.3%-3.2%-6.0%
Q1 2022+48.2%+59.2%+106.2%
Q4 2021+11.9%+42.9%+98.4%
Q3 2021-0.8%+11.6%+30.1%
Q2 2021-3.8%-5.6%+35.7%
Q1 2021+0.6%+3.5%+9.8%
Q3 2020+3.7%+0.7%+22.2%
Q2 2020+2.5%+8.7%-11.3%
Q1 2020-17.9%-23.7%+18.4%
Q4 2019+5.1%+2.6%-47.1%
Q3 2019-4.4%-3.9%-12.7%
Q2 2019+8.1%+1.9%+8.4%
Q1 2019+0.0%-0.8%-14.7%
Q4 2018-8.7%-14.0%-6.2%
Q3 2018-2.1%-6.1%-12.0%
Q2 2018+1.3%+1.1%+0.0%
Q1 2018+0.2%+2.6%+3.0%
Q4 2017-2.8%-3.4%-7.7%
Q3 2017+7.7%+16.0%+16.2%
Q2 2017-1.5%+2.3%-0.4%
Q1 2017-0.6%+3.7%+13.1%
Q4 2016-4.7%-10.2%-17.9%
Q3 2016-10.7%-11.3%+5.3%
Q2 2016-0.9%-3.2%+2.8%
Q1 2016+0.6%
Q4 2015-5.6%
Q3 2015-1.1%
Q2 2015-8.2%
Q1 2015-5.3%
Q4 2014+8.1%
Q3 2014+6.3%
Q2 2014+6.7%
Q1 2014-0.5%
Q4 2013+0.6%
Q3 2013-2.9%
Q2 2013-0.9%
Q1 2013+4.6%
Q4 2012-0.9%
Q3 2012+0.9%
Q2 2012+2.0%
Q1 2012-2.5%
Q4 2011-0.2%
Q3 2011+0.2%
Q3 2010+0.2%
Q2 2010-1.0%
Q2 2011-1.0%
Q1 2011-2.1%
Q4 2010+6.5%
Q1 2010+5.1%
Q4 2009-1.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro